Close Menu

NEW YORK – Fulgent Genetics reported after the close of the market on Tuesday that its second quarter revenues more than doubled, driven by multiple types of tests to detect COVID-19.

For the three-month period ended June 30, Fulgent's revenues grew to a record $17.3 million from $8.4 million in Q2 2019, handily beating the average Wall Street analysts' estimate of $10 million. The number of billable tests delivered during the quarter grew over tenfold year over year to 180,513 tests.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.